Sage Shares Below $50, One Of The Best Opportunities In Stifel's Coverage
March 01, 2020 at 15:02 PM EST
Stifel analyst, Paul Matteis says Sage Therapeutics (SAGE) shares below $50 represent one of the best opportunities in Stifel's coverage universe.